Exceptional 30-year survival of a patient with multiple myeloma – quality of life and management of disease-related symptoms

Patrycja Lebowa; Weronika Marzena Lebowa; Artur Jurczyszyn

doi:10.5114/pm.2024.143808

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla onkologów!

www.eonkologia.pl

Wyszukiwanie

3/2024
vol. 16

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

Opis przypadku

Exceptional 30-year survival of a patient with multiple myeloma – quality of life and management of disease-related symptoms

Patrycja Lebowa

¹

,

Weronika Marzena Lebowa

²

,

Artur Jurczyszyn

³

Student Scientific Group at the Department and Clinic of Hematology, Jagiellonian University Medical College, Kraków, Poland
Doctoral School of Medical and Health Sciences, Department of Hematology and Internal Medicine, University Hospital, Jagiellonian University Medical College, Kraków, Poland
Department of Hematology and Internal Medicine, University Hospital, Jagiellonian University Medical College, Kraków, Poland

Medycyna Paliatywna 2024; 16(3): 200–204

DOI: https://doi.org/10.5114/pm.2024.143808

Data publikacji online: 2024/09/30

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

Multiple myeloma (MM) is a chronic plasma cell malignancy with a median survival of about 8–10 years. Despite the development of many new drugs in recent years, disease recurrence is inevitable. The current critical unmet need is the management of heavily pretreated patients with refractory MM. We present the case of a 65-year-old male patient with an exceptionally long-term 30-year course of MM treated with 13 treatment lines. The patient struggles with many disease-related symptoms and treatment toxicity. The patient is currently treated with a triplet regimen including isatuximab, pomalidomide, and dexamethasone. Overall survival of 30 years, which is 3 times greater than the median survival in MM, is still rare, but achievable. In addition to anticancer treatment, supportive care is very important to alleviate myeloma symptoms and improve quality of life. To our knowledge, this is one of the published clinical cases with the longest survival in MM.

POLECAMY

KSIĄŻKI

• Medycyna Paliatywna

Exceptional 30-year survival of a patient with multiple myeloma – quality of life and management of disease-related symptoms

Patrycja Lebowa 1 , Weronika Marzena Lebowa 2 , Artur Jurczyszyn 3

Patrycja Lebowa

¹

,

Weronika Marzena Lebowa

²

,

Artur Jurczyszyn

³